SCHEMBL21801296

SCHEMBL21801296

COc1ccc(Cn2cnc3c(OC)nc(Cl)nc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 9/20 0.56
HPGD P15428 1/20 0.55
PDE8A O60658 1/20 0.52
CCNE2 O96020 1/20 0.51
CCNE1 P24864 1/20 0.51
CDK2 P24941 1/20 0.51
ADORA2A P29274 1/20 0.51
CTSL P07711 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MET P08581 1/20 0.46
CNR2 P34972 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30496438 1.00 YTHDC1 (0.56) YTHDC1HPGDPDE8ACCNE2CCNE1
SCHEMBL18554311 0.88 HPGD (0.67) YTHDC1HPGDPDE8ACCNE2CCNE1
SCHEMBL29365706 0.88 HPGD (0.67) YTHDC1HPGDPDE8ACCNE2CCNE1
SCHEMBL3821565 0.88 YTHDC1 (0.57) YTHDC1HPGDPDE8ACCNE2CCNE1
SCHEMBL23635091 0.87 HPGD (0.59) YTHDC1HPGDPDE8ACCNE2CCNE1
SCHEMBL5462820 0.85 ADORA2A (0.54) YTHDC1HPGDPDE8ACCNE2CCNE1
SCHEMBL30747798 0.82 CCNE2 (0.77) YTHDC1CCNE2CCNE1CDK2CTSL
SCHEMBL27249486 0.82 CCNE2 (0.77) YTHDC1CCNE2CCNE1CDK2CTSL
SCHEMBL17262805 0.81 YTHDC1 (0.59) YTHDC1HPGDPDE8AADORA2ACTSL
SCHEMBL17364311 0.80 CDK1 (0.46) YTHDC1PDE8ACCNE1CDK2ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12157739-B2 Hypoxanthine compounds KISSEI PHARMACEUTICAL CO., LTD. (JP) 2024-12-03 US disclosed
CN-112673008-B Hypoxanthine compounds 橘生药品工业株式会社 2023-07-18 CN disclosed
US-20210214357-A1 HYPOXANTHINE COMPOUNDS KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-07-15 US disclosed
EP-3819299-A1 HYPOXANTHINE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-05-12 EP disclosed
EP-3819299-A1 HYPOXANTHINE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-05-12 EP disclosed
CN-112673008-A Hypoxanthine compound 橘生药品工业株式会社 2021-04-16 CN disclosed
WO-2020054825-A1 HYPOXANTHINE COMPOUND キッセイ薬品工業株式会社 2020-03-19 WO disclosed
WO-2020054825-A1 HYPOXANTHINE COMPOUND キッセイ薬品工業株式会社 2020-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157739-B2 Hypoxanthine compounds HPRT1, APRT, IMPDH1 YTHDC1 651/4885HPGD 49/4885PDE8A 512/4885
US-20210214357-A1 HYPOXANTHINE COMPOUNDS HPRT1, DHPS, PAH YTHDC1 611/4885HPGD 56/4885PDE8A 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.